# EDGAR Filing Document

**Accession Number:** 0001888886
**File Stem:** 0001104659-26-020645
**Filing Date:** 2026-2
**Character Count:** 26399
**Document Hash:** be4573d4ae57e83fc5f5e84e6bfe7a98
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-020645.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001104659-26-020645

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**EFFECTIVENESS DATE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Structure Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001888886
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981480821
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293821
- **FILM NUMBER:** 26690621

**BUSINESS ADDRESS:**
- **STREET 1:** 601 GATEWAY BLVD SUITE 900
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (650) 457-1978

**MAIL ADDRESS:**
- **STREET 1:** 601 GATEWAY BLVD SUITE 900
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ShouTi Inc.
- **DATE OF NAME CHANGE:** 20211019

**As filed with the Securities and Exchange Commission on February 26, 2026**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

------

**Structure Therapeutics Inc.**

**(Exact name of registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| **Cayman Islands** | **98-1480821** |
| **(State or other jurisdiction of<br> incorporation or organization)** | **(I.R.S. Employer<br> Identification Number)** |

---

---

| | |
|:---|:---|
| **601 Gateway Blvd., Suite 900<br> South San Francisco, CA** | **94080** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2023 Equity Incentive Plan**

**2023 Employee Share Purchase Plan**

**(Full titles of the plans)**

------

**Raymond Stevens, Ph.D.**

**Chief Executive Officer**

**Structure Therapeutics Inc.**

**601 Gateway Blvd., Suite 900**

**South San Francisco, CA**

**(650) 457-1978**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

------

***Copies to*** **:**

**Patrick Loofbourrow**

**Carlos Ramirez**

**Su Lian Lu**

**Cooley LLP**

**10265 Science Center Drive**

**San Diego, California 92121**

**(858) 550-6000**

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | ◻ |
| Non-accelerated filer | ◻ | Smaller reporting company | ◻ |
| Emerging growth company | ◻ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed by Structure Therapeutics Inc. (the "***Registrant***") for the purpose of registering (i) an additional 8,500,536 ordinary shares of the Registrant, $0.0001 par value per share ("***Ordinary Shares***") (an equivalent of 2,833,512 American Depositary Shares ("***ADSs***")), under the Registrant's 2023 Equity Incentive Plan (the "***2023 Plan***"), pursuant to the provisions of the 2023 Plan providing for an automatic increase in the number of Ordinary Shares reserved and available for issuance under the 2023 Plan, and (ii) an additional 2,125,134 Ordinary Shares (an equivalent of 708,378 ADSs), under the Registrant's 2023 Employee Share Purchase Plan (the "***2023 ESPP***") pursuant to the provisions of the 2023 ESPP providing for an automatic increase in the number of Ordinary Shares reserved and available for issuance under the 2023 ESPP, in each case on January 1, 2026.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.** **Incorporation of Documents by Reference**

The following documents filed by the Registrant with the U.S. Securities and Exchange Commission (the "***Commission***") are incorporated by reference into this Registration Statement:

(a) the contents of the Registration Statement on Form S-8 previously filed with the Commission on [February 6, 2023](https://www.sec.gov/Archives/edgar/data/1888886/000110465923011247/tm235561d1_s8.htm) (File No. 333-269601), [March 8, 2024](https://www.sec.gov/Archives/edgar/data/1888886/000110465924032400/tm247466d1_s8.htm) (File No. 333-277789) and [February 27, 2025](https://www.sec.gov/Archives/edgar/data/1888886/000110465925018327/tm257214d1_s8.htm) (File No. 333-285377);

(b) the Registrant's Annual Report on Form 10-K for the fiscal
 year ended December 31, 2025, which includes audited financial statements for the Registrant's
 latest fiscal year, filed with the Commission on [February 26, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001888886/000110465926020562/gpcr-20251231x10k.htm) ;

(c) The Registrant's Current Report on Form 8-K, filed with the Securities and Exchange Commission
on [January 5, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1888886/000110465926000620/tm261919d1_8k.htm) (File No. 001-41608); and

(d) the description of the registrant's Ordinary Shares contained in the registrant's registration statement
on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1888886/000110465923007953/tm234457d1_8a12b.htm) (File No. 001-41608), filed with the Commission on January 30, 2023,
including any amendments or reports filed for the purpose of updating such description, including [Exhibit 4.5](https://www.sec.gov/Archives/edgar/data/1888886/000155837023005141/gpcr-20221231xex4d5.htm) to the registrant's Annual Report on Form 10-K for the year ended December 31, 2022.

All reports and other documents subsequently filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports or portions thereof furnished under Item 2.02 or Item 7.01 or any related Item 9.01 of Form 8-K and exhibits furnished on such form that relate to such items and other portions of documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the Commission, after the date of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities offered hereby then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing such reports and documents.

Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this registration statement, except as so modified or superseded.

---

| | |
|:---|:---|
| **Item 8.**<br>**Exhibit<br> Number** | **Exhibits** <br>**Description** |
| [4.1](https://www.sec.gov/Archives/edgar/data/1888886/000110465923011717/tm235639d1_ex3-1.htm) | [Amended and Restated Memorandum and Articles of Association of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-41608) filed on February 7, 2023).](https://www.sec.gov/Archives/edgar/data/1888886/000110465923011717/tm235639d1_ex3-1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1888886/000110465923007657/tm225197d15_ex4-1.htm) | [Registrant's Specimen Certificate for Ordinary Shares (incorporated herein by reference to Exhibit 4.1 to the Registration Statement on Form S-1, as amended (File No. 333-269200)).](https://www.sec.gov/Archives/edgar/data/1888886/000110465923007657/tm225197d15_ex4-1.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/1888886/000110465923007657/tm225197d15_ex4-2.htm) | [Form of Deposit Agreement (incorporated herein by reference to Exhibit 4.2 to the Registration Statement on Form S-1, as amended (File No. 333-269200)).](https://www.sec.gov/Archives/edgar/data/1888886/000110465923007657/tm225197d15_ex4-2.htm) |
| [4.4](https://www.sec.gov/Archives/edgar/data/1888886/000110465923007657/tm225197d15_ex4-2.htm) | [Form of American Depositary Receipt evidencing American Depositary Shares (included in Exhibit 4.3).](https://www.sec.gov/Archives/edgar/data/1888886/000110465923007657/tm225197d15_ex4-2.htm) |
| [5.1\*](tm267169d1_ex5-1.htm) | [Opinion of Travers Thorp Alberga, regarding the validity of the ordinary shares being registered.](tm267169d1_ex5-1.htm) |
| [23.1\*](tm267169d1_ex23-1.htm) | [Consent of independent registered public accounting firm.](tm267169d1_ex23-1.htm) |
| [23.2\*](tm267169d1_ex5-1.htm) | [Consent of Travers Thorp Alberga (included in Exhibit 5.1).](tm267169d1_ex5-1.htm) |
| [24.1\*](#Ea_001) | [Powers of Attorney (included on the signature page).](#Ea_001) |
| [99.1](https://www.sec.gov/Archives/edgar/data/1888886/000155837023005141/gpcr-20221231xex10d3.htm) | [Structure Therapeutics Inc. 2023 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (File No. 001-41608)).](https://www.sec.gov/Archives/edgar/data/1888886/000155837023005141/gpcr-20221231xex10d3.htm) |
| [99.2](https://www.sec.gov/Archives/edgar/data/1888886/000110465923003415/tm225197d11_ex10-4.htm) | [Form of Share Option Grant Notice, Share Option Agreement and Notice of Exercise (US) under the Structure Therapeutics Inc. 2023 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.4 to the Registration Statement on Form S-1, as amended (File No. 333-269200)).](https://www.sec.gov/Archives/edgar/data/1888886/000110465923003415/tm225197d11_ex10-4.htm) |
| [99.2](https://www.sec.gov/Archives/edgar/data/1888886/000110465923003415/tm225197d11_ex10-5.htm) | [Form of Share Option Grant Notice, Share Option Agreement and Notice of Exercise (Non-Employee Director) under the Structure Therapeutics Inc. 2023 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Registration Statement on Form S-1, as amended (File No. 333-269200)).](https://www.sec.gov/Archives/edgar/data/1888886/000110465923003415/tm225197d11_ex10-5.htm) |
| [99.4](https://www.sec.gov/Archives/edgar/data/1888886/000110465923003415/tm225197d11_ex10-6.htm) | [Form of Share Option Grant Notice, Share Option Agreement and Notice of Exercise (PRC) under the Structure Therapeutics Inc. 2023 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.6 to the Registration Statement on Form S-1, as amended (File No. 333-269200)).](https://www.sec.gov/Archives/edgar/data/1888886/000110465923003415/tm225197d11_ex10-6.htm) |
| [99.5](https://www.sec.gov/Archives/edgar/data/1888886/000110465923003415/tm225197d11_ex10-7.htm) | [Form of Restricted Share Unit Award Grant Notice and Award Agreement (US) under the Structure Therapeutics Inc. 2023 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.7 to the Registration Statement on Form S-1, as amended (File No. 333-269200)).](https://www.sec.gov/Archives/edgar/data/1888886/000110465923003415/tm225197d11_ex10-7.htm) |
| [99.6](https://www.sec.gov/Archives/edgar/data/1888886/000110465923003415/tm225197d11_ex10-8.htm) | [Form of Restricted Share Unit Award Grant Notice and Award Agreement (PRC) under the Structure Therapeutics Inc. 2023 Equity Incentive Plan. (incorporated herein by reference to Exhibit 10.8 to the Registration Statement on Form S-1, as amended (File No. 333-269200)).](https://www.sec.gov/Archives/edgar/data/1888886/000110465923003415/tm225197d11_ex10-8.htm) |
| [99.7](https://www.sec.gov/Archives/edgar/data/1888886/000155837023005141/gpcr-20221231xex10d9.htm) | [Structure Therapeutics Inc. 2023 Employee Share Purchase Plan (incorporated herein by reference to Exhibit 10.9 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (File No. 001-41608)).](https://www.sec.gov/Archives/edgar/data/1888886/000155837023005141/gpcr-20221231xex10d9.htm) |
| [107\*](tm267169d1_exfilingfee.htm) | [Filing Fee Table.](tm267169d1_exfilingfee.htm) |

---

\* Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on February 26, 2026.

---

| | |
|:---|:---|
| **Structure Therapeutics Inc.** | **Structure Therapeutics Inc.** |
| By: | /s/ Raymond Stevens, Ph.D. |
|  | Raymond Stevens, Ph.D. |
|  | *Chief Executive Officer* |

---

**POWER OF ATTORNEY**

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Raymond Stevens, Ph.D. and Jun Yoon, and each of them, his or her true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution, for and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Raymond Stevens, Ph.D. | Chief Executive Officer and Director | February 26, 2026 |
| Raymond Stevens, Ph.D. | *(Principal Executive Officer)* |  |
| /s/ Jun Yoon | Chief Financial Officer | February 26, 2026 |
| Jun Yoon | (*Principal Financial and Accounting Officer*) |  |
| /s/ Daniel Welch | Chairman | February 26, 2026 |
| Daniel Welch |  |  |
| /s/ Eric Dobmeier | Director | February 26, 2026 |
| Eric Dobmeier |  |  |
| /s/ Ted W. Love, M.D. | Director | February 26, 2026 |
| Ted W. Love, M.D. |  |  |
| /s/ Angus Russell | Director | February 26, 2026 |
| Angus Russell |  |  |
| /s/ Sharon Tetlow | Director | February 26, 2026 |
| Sharon Tetlow |  |  |
| /s/ Joanne Waldstreicher, M.D. | Director | February 26, 2026 |
| Joanne Waldstreicher, M.D. |  |  |

---

**SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE**

Pursuant to the requirements of the Securities Act of 1933, as amended, the duly authorized representative in the United States of Structure Therapeutics Inc., has signed this registration statement on February 26, 2026.

---

| | |
|:---|:---|
| **Authorized U.S. Representative** | **Authorized U.S. Representative** |
| **RAYMOND STEVENS, PH.D.** | **RAYMOND STEVENS, PH.D.** |
| By: | /s/ Raymond Stevens, Ph.D. |
|  | Raymond Stevens, Ph.D. |
|  | *Chief Executive Officer* |

---

## Exhibit 5.1

**Exhibit 5.1**

![](tm267169d1_ex5-1img001.jpg)

Structure Therapeutics Inc.

Harbour Place, 2nd Floor, North Wing

103 South Church Street

P.O. Box 472, George Town

Grand Cayman KYI-1106

Cayman Islands

26 February 2026

**Structure Therapeutics Inc.**

We have examined the Registration Statement on Form S-8 to be filed by Structure Therapeutics Inc., a Cayman Islands exempted company incorporated with limited liability (the "**Registrant**"), with the Securities and Exchange Commission (the "**Registration Statement**"), relating to the registration under the Securities Act of 1933, as amended, of an amount of ordinary shares of the Registrant (the "**Shares**") for issuance pursuant to the Structure Therapeutics Inc. 2023 Equity Incentive Plan and the 2023 Employee Share Purchase Plan (together, the "**Plans**").

As Cayman Islands counsel to the Registrant, we have examined the corporate authorisations of the Registrant in connection with the Plans and the issue of the Shares by the Registrant and have assumed that the Shares will be issued in accordance with the Plans and the resolutions authorizing the issue.

It is our opinion that the Shares to be issued by the Registrant have been duly and validly authorised, and when issued, sold and paid for in the manner described in the Plans and in accordance with the relevant resolutions adopted by the Board of Directors and/or the shareholders of the Registrant (or any committee to whom the Board of Directors have delegated their powers with respect to administration of the Plans) and when appropriate entries have been made in the Register of Members of the Registrant, will be legally issued, fully paid and non-assessable.

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to all references to us in the Registration Statement and any amendments thereto.

Yours faithfully

**TRAVERS THORP ALBERGA**

![](tm267169d1_ex5-1img002.jpg)

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2023 Equity Incentive Plan and 2023 Employee Share Purchase Plan of Structure Therapeutics Inc. of our reports dated February 26, 2026, with respect to the consolidated financial statements of Structure Therapeutics Inc. and the effectiveness of internal control over financial reporting of Structure Therapeutics Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Mateo, California

February 26, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Structure Therapeutics Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Ordinary shares, $0.0001 par value per share, issuable under the Structure Therapeutics Inc. 2023 Equity Incentive Plan | Other | 8500536 | $22.20 | $188711899.20 | 0.0001381 | $26061.11 |
| 2 | Equity | Ordinary shares, $0.0001 par value per share, issuable under the Structure Therapeutics Inc. 2023 Employee Share Purchase Plan | Other | 2125134 | $18.87 | $40101278.58 | 0.0001381 | $5537.99 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $228813177.78  |  | $31599.10  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $31599.10  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (a) The ordinary shares, $0.0001 par value per share ("Ordinary Shares"), of Structure Therapeutics Inc. (the "Registrant") are represented by American Depositary Shares ("ADSs"), each representing three Ordinary Shares. (b) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional Ordinary Shares that become issuable under the 2023 Equity Incentive Plan (the "2023 Plan"), or the 2023 Employee Share Purchase Plan (the "2023 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction. (c) Estimated in accordance with Rules 457(c) and 457(h)(1) promulgated under the Securities Act solely for the purpose of calculating the registration fee, and is based upon the price of $22.20 per Ordinary Share (or the equivalent of $66.60 per ADS), which was the average of the high and low prices of the Registrant's ADSs as reported on the Nasdaq Global Market on February 19, 2026. (d) Represents 8,500,536 Ordinary Shares (an equivalent of 2,833,512 ADSs) that were automatically added to the shares authorized for issuance under the 2023 Plan on January 1, 2026 pursuant to an "evergreen" provision contained in the 2023 Plan. The 2023 Plan provides that, on January 1st of each year through (and including) January 1, 2033, the number of shares authorized for issuance under the 2023 Plan is automatically increased by a number equal to (a) 4% of the total number of Ordinary Shares outstanding on December 31st of the preceding year; or (b) such lesser number of Ordinary Shares as the Registrant's board of directors (the "Board") may designate prior to the applicable January 1st.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> (a) The Ordinary Shares of the Registrant are represented by ADSs, each representing three Ordinary Shares. (b) Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional Ordinary Shares that become issuable under the 2023 Plan, or the 2023 ESPP by reason of any stock dividend, stock split, recapitalization or other similar transaction. (c) Estimated in accordance with Rules 457(c) and 457(h)(1) promulgated under the Securities Act solely for the purpose of calculating the registration fee, and is based upon the price of $18.87 per Ordinary Share (or the equivalent of $56.61 per ADS), which was the average of the high and low prices of the Registrant's ADSs as reported on the Nasdaq Global Market on February 19, 2026, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the 2023 ESPP. (d) Represents 2,125,134 Ordinary Shares (an equivalent of 708,378 ADSs) that were automatically added to the shares authorized for issuance under the 2023 ESPP. The 2023 ESPP provides that, on January 1st of each year through (and including) January 1, 2033, the number of shares authorized for issuance under the 2023 ESPP is automatically increased by a number equal to the lesser of: (i) 1% of the total number of Ordinary Shares outstanding on December 31st of the preceding year; (ii) 3,000,000 Ordinary Shares; or (iii) such lesser number of Ordinary Shares as the Board may designate prior to the applicable January 1st.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---